Alkem Lab announces exclusive licensing agreement with Johns Hopkins University

31 Jan 2022 , 03:16 PM

Alkem Laboratories Limited (Alkem), one of India’s largest global pharmaceutical companies, has announced that the company has entered into an exclusive e license agreement for the development and commercialization of Johns Hopkins University (JHU’s) novel target and technology that will help patients with colorectal cancer. This technology will serve as a bona fide biomarker and antagonist in human colorectal cancer based on angiogenesis and inflammation, company said in a filing. 

“This collaboration is a stepping stone to a long-term symbiotic relationship between JHU and Alkem, to help bring novel therapies to market,” commented Alkem’s Managing Director, Mr. Sandeep Singh.

He further added, “We aspire that this will be a significant step in fostering continued academic and clinical collaboration between Alkem and JHU for addressing unmet patient needs.” He further added that Alkem will be working with the Director of the Sphingolipid Signaling and Vascular Biology Laboratory at the Johns Hopkins University School of Medicine on this novel target”.

Alkem Laboratories was established in 1973, and is headquartered in Mumbai is a leading Indian pharmaceutical company engaged in overall operations of pharmaceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it sells in Indian and International markets. With a portfolio of more than 800 brands in India, it is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The Company also has a presence in more than 40 international markets, with the United States being its key focus market.

Alkem Laboratories Ltd is currently trading at Rs3,538 up by Rs122.1 or 3.57% from its previous closing of Rs3,415.90 on the BSE. The scrip opened at Rs3,449.90 and has touched an intraday high and low of Rs3,565.40 and Rs3,411.80 respectively.